Q3 2026 J B Chemicals and Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- J.B. Chemicals & Pharmaceuticals Ltd (BOM:506943) reported a strong revenue growth of 11% year-on-year, reaching INR1,065 crores.
- The company's operating EBITDA, excluding non-cash ESOP, increased by 13% to INR305 crores.
- Net profit saw a significant rise of 22% year-on-year, amounting to INR198 crores.
- Gross margins improved by 200 basis points to 69.1%, driven by an attractive product mix and stable raw material costs.
- The international operations experienced a robust growth of 12% year-on-year, with strong performances in markets like Russia, South Africa, and the USA.
- The CDMO business remained nearly flat at INR117 crores for the quarter, indicating a slowdown compared to previous growth rates.
- There was a noted slowdown in the acute gastro segment within the domestic market, impacting overall growth.
- The company did not announce an interim dividend, which deviates from its regular practice over the past five years.
- The merger with Torrent is still in progress with no definitive timeline, causing uncertainty among investors.
- The domestic business growth was slightly below expectations, attributed to inventory closing issues in March, a common phenomenon in the Indian pharmaceutical market.
Ladies and gentlemen, good day and welcome to JB Pharma's Q3 FY26 earnings conference call on January 19, 2026. (Operator Instructions) Please note that this conference is being recorded. I now want the conference over to Mr. Jason Dsouza, Executive Vice President at JB Pharma.
Thank you and over to you, Mr. Desouza.
Thank you, Andrew. Welcome to the earnings call of JB Pharma. We have with us today, Nikhil Chopra, CEO and Whole-time Director, Mr. Kunal Khanna, President Operations, Narayan Saraf, the CFO at JB Chemicals and Pharmaceuticals Limited.
Before we begin, I would like to state that some of the statements in today's discussion may be forward-looking in nature and may involve certain risks and uncertainties. A detailed statement in this regard is available in the results presentation that has been sent to you earlier. I would like to hand over the floor to Mr. Nikhil Chopra to begin the proceedings of the call and for his opening remarks.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
